Logo image of AXNX

Axonics Inc (AXNX) Stock Fundamental Analysis

NASDAQ:AXNX - Nasdaq - US05465P1012 - Common Stock - Currency: USD

70.98  +0.53 (+0.75%)

After market: 70.98 0 (0%)

Fundamental Rating

5

Overall AXNX gets a fundamental rating of 5 out of 10. We evaluated AXNX against 187 industry peers in the Health Care Equipment & Supplies industry. AXNX has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, AXNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year AXNX has reported negative net income.
In the past year AXNX had a positive cash flow from operations.
In the past 5 years AXNX always reported negative net income.
In the past 5 years AXNX reported 4 times negative operating cash flow.
AXNX Yearly Net Income VS EBIT VS OCF VS FCFAXNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of AXNX (-0.73%) is better than 67.91% of its industry peers.
AXNX has a better Return On Equity (-0.85%) than 68.98% of its industry peers.
Industry RankSector Rank
ROA -0.73%
ROE -0.85%
ROIC N/A
ROA(3y)-8.17%
ROA(5y)-15.38%
ROE(3y)-9.34%
ROE(5y)-18.16%
ROIC(3y)N/A
ROIC(5y)N/A
AXNX Yearly ROA, ROE, ROICAXNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300 400

1.3 Margins

The Gross Margin of AXNX (76.59%) is better than 89.30% of its industry peers.
AXNX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for AXNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.58%
GM growth 5Y5.57%
AXNX Yearly Profit, Operating, Gross MarginsAXNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

AXNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AXNX has been increased compared to 1 year ago.
AXNX has more shares outstanding than it did 5 years ago.
AXNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AXNX Yearly Shares OutstandingAXNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
AXNX Yearly Total Debt VS Total AssetsAXNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 20.38 indicates that AXNX is not in any danger for bankruptcy at the moment.
AXNX has a Altman-Z score of 20.38. This is amongst the best in the industry. AXNX outperforms 93.58% of its industry peers.
AXNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 20.38
ROIC/WACCN/A
WACC9.07%
AXNX Yearly LT Debt VS Equity VS FCFAXNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

AXNX has a Current Ratio of 8.16. This indicates that AXNX is financially healthy and has no problem in meeting its short term obligations.
AXNX has a better Current ratio (8.16) than 87.70% of its industry peers.
AXNX has a Quick Ratio of 6.40. This indicates that AXNX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AXNX (6.40) is better than 85.03% of its industry peers.
Industry RankSector Rank
Current Ratio 8.16
Quick Ratio 6.4
AXNX Yearly Current Assets VS Current LiabilitesAXNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

AXNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -116.67%.
AXNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.08%.
AXNX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 249.76% yearly.
EPS 1Y (TTM)-116.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y48.67%
Revenue growth 5Y249.76%
Sales Q2Q%24.8%

3.2 Future

AXNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 69.51% yearly.
The Revenue is expected to grow by 19.14% on average over the next years. This is quite good.
EPS Next Y56.54%
EPS Next 2Y120.11%
EPS Next 3Y100.31%
EPS Next 5Y69.51%
Revenue Next Year23.72%
Revenue Next 2Y21.8%
Revenue Next 3Y20.53%
Revenue Next 5Y19.14%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AXNX Yearly Revenue VS EstimatesAXNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
AXNX Yearly EPS VS EstimatesAXNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AXNX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 81.39 indicates a quite expensive valuation of AXNX.
Based on the Price/Forward Earnings ratio, AXNX is valued a bit cheaper than 65.78% of the companies in the same industry.
AXNX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.70.
Industry RankSector Rank
PE N/A
Fwd PE 81.39
AXNX Price Earnings VS Forward Price EarningsAXNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -2K -4K -6K

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AXNX indicates a somewhat cheap valuation: AXNX is cheaper than 62.57% of the companies listed in the same industry.
AXNX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AXNX is cheaper than 66.84% of the companies in the same industry.
Industry RankSector Rank
P/FCF 675.06
EV/EBITDA 603.04
AXNX Per share dataAXNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AXNX's earnings are expected to grow with 100.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y120.11%
EPS Next 3Y100.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AXNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Axonics Inc

NASDAQ:AXNX (11/14/2024, 8:04:51 PM)

After market: 70.98 0 (0%)

70.98

+0.53 (+0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners85.44%
Inst Owner Change-84.06%
Ins Owners5.35%
Ins Owner Change0%
Market Cap3.63B
Analysts68.42
Price Target73.33 (3.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.5%
Min EPS beat(2)-100%
Max EPS beat(2)-1.01%
EPS beat(4)1
Avg EPS beat(4)-49.29%
Min EPS beat(4)-215.13%
Max EPS beat(4)118.99%
EPS beat(8)5
Avg EPS beat(8)52.84%
EPS beat(12)9
Avg EPS beat(12)41.69%
EPS beat(16)11
Avg EPS beat(16)30.84%
Revenue beat(2)2
Avg Revenue beat(2)0.21%
Min Revenue beat(2)0.05%
Max Revenue beat(2)0.37%
Revenue beat(4)3
Avg Revenue beat(4)0.07%
Min Revenue beat(4)-0.36%
Max Revenue beat(4)0.37%
Revenue beat(8)7
Avg Revenue beat(8)1.85%
Revenue beat(12)11
Avg Revenue beat(12)3.83%
Revenue beat(16)13
Avg Revenue beat(16)4.5%
PT rev (1m)0.23%
PT rev (3m)0.23%
EPS NQ rev (1m)21.53%
EPS NQ rev (3m)21.53%
EPS NY rev (1m)-2.83%
EPS NY rev (3m)5.04%
Revenue NQ rev (1m)0.94%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 81.39
P/S 8.4
P/FCF 675.06
P/OCF 253.73
P/B 5.46
P/tB 7.53
EV/EBITDA 603.04
EPS(TTM)-0.01
EYN/A
EPS(NY)0.87
Fwd EY1.23%
FCF(TTM)0.11
FCFY0.15%
OCF(TTM)0.28
OCFY0.39%
SpS8.45
BVpS13
TBVpS9.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.73%
ROE -0.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.59%
FCFM 1.24%
ROA(3y)-8.17%
ROA(5y)-15.38%
ROE(3y)-9.34%
ROE(5y)-18.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.58%
GM growth 5Y5.57%
F-Score6
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 71.48%
Cap/Sales 2.07%
Interest Coverage N/A
Cash Conversion 271.41%
Profit Quality N/A
Current Ratio 8.16
Quick Ratio 6.4
Altman-Z 20.38
F-Score6
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)24.04%
Cap/Depr(5y)70.74%
Cap/Sales(3y)1.01%
Cap/Sales(5y)3.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y56.54%
EPS Next 2Y120.11%
EPS Next 3Y100.31%
EPS Next 5Y69.51%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y48.67%
Revenue growth 5Y249.76%
Sales Q2Q%24.8%
Revenue Next Year23.72%
Revenue Next 2Y21.8%
Revenue Next 3Y20.53%
Revenue Next 5Y19.14%
EBIT growth 1Y33.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year377.96%
EBIT Next 3Y82.88%
EBIT Next 5Y66.14%
FCF growth 1Y133.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y210.5%
OCF growth 3YN/A
OCF growth 5YN/A